News Wire

A spate of acquisitions in the health care industry may change the way U.S. employers design their future health care strategies and alter the way individuals access health care in the future, according to a survey from the consultant Aon. On December 14, Aon asked 450 human resources leaders from large…
Rapidly dividing aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer––a finding that could upend the way scientists think about the origin of the disease. Researchers at Washington University School of Medicine in…
After reviewing the latest research, the FDA has reaffirmed its 2014 warning that power morcellators should rarely be used in gynecological surgery because of the risk of spreading a hidden uterine cancer. According to a report in the Philadelphia Inquirer, the FDA said the latest studies are consistent…
Nearly one in three students in 12th grade report past-year use of a vaping device, raising concerns about the impact on their health. What they say is in the device, however, ranges from nicotine to marijuana to “just flavoring,” according to the 2017 Monitoring the Future (MTF) survey of eighth,…
The FDA has approved ozenoxacin cream, 1% (Xepi, Medimetriks Pharmaceuticals, Inc.) for the treatment of impetigo in patients 2 months of age and older. The product is applied topically twice daily for five days. In the U.S., impetigo is estimated to account for approximately 10% of skin problems observed…
It’s shaping up to be a bumper year for drug approvals, with U.S. officials clearing twice as many novel medicines as in 2016, yet returns on research investment at leading pharmaceutical companies are down. In fact, projected returns at 12 of the world’s top drugmakers have fallen to an eight-year…
The FDA has approved infliximab-qbtx (Ixifi, Pfizer), the third biosimilar to Remicade (Johnson and Johnson)––and the second one from Pfizer, which already markets Inflectra in the U.S. Pfizer and Celltrion Inc. launched Inflectra in late 2016. The other Remicade biosimilar, Renflexis, is made by…
The FDA, seeking to get critical updates on antibiotics and antifungal drugs to health care professionals more quickly, has created a website that will provide direct and timely access to information about when bacterial or fungal infections are likely to respond to a specific drug. The new tool is…
The Pharmaceutical Research and Manufacturers of America (PhRMA) has announced a multiyear, multimillion-dollar initiative to address the opioid crisis, which will include a partnership with the Addiction Policy Forum to fund state and local programs, as well as support for new public policies that…
The FDA has approved the Vercise Deep Brain Stimulation (DBS) System (Boston Scientific Corporation) to treat the symptoms of Parkinson’s disease (PD), a degenerative condition that affects more than one million people in the United States and 10 million worldwide. DBS works by stimulating a targeted…
Omeros Corporation has received FDA approval to expand the indication for Omidria (phenylephrine and ketorolac intraocular solution) 1%/0.3% to include use in pediatric patients (from birth through 17 years). Omidria is used during cataract surgery or intraocular lens replacement to prevent intraoperative…
The FDA has approved Admelog (insulin lispro injection, Sanofi-Aventis U.S.), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients ages 3 years and older with type-1 diabetes mellitus and adults with type-2 diabetes mellitus. Admelog is the first…
The FDA has expanded the approved use of mepolizumab (Nucala, GlaxoSmithKline) to treat adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune disease that causes vasculitis, an inflammation in the wall of blood vessels of the body. This new indication provides the…
A year or more after a single infusion of axicabtagene ciloleucel (Yescarta, Gilead Sciences), 42% of lymphoma patients continued to respond to therapy––including 40% with a complete remission.  Gilead’s Kite subsidiary announced long-term follow-up data from the pivotal ZUMA-1 study of axicabtagene…
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) improved progression-free survival compared with sunitinib (Sutent, Pfizer) as initial treatment for patients whose advanced kidney disease expressed programmed death-ligand 1 (PD-L1) in the phase 3 IMmotion151 trial, Genentech has…

Pages